Sharescart Research Club logo
Products
Research
Tools
About
  • Home
  • /
  • Glenmark Pharma
Join Channel
Consolidated Standalone

Glenmark Pharma

₹1855.4 2.6 | 0.1%

Market Cap ₹52360 Cr.

Stock P/E 50

P/B 5.9

Current Price ₹1855.4

Book Value ₹ 314.9

Face Value 1

52W High ₹2286.2

Dividend Yield 0.13%

52W Low ₹ 1274.7

Edit Ratio

Glenmark Pharma Research see more...

Overview Inc. Year: 1977Industry: Pharmaceuticals & Drugs

Glenmark Pharmaceuticals Ltd is a international pharmaceutical corporation. The Company is commonly engaged in the enterprise of developing, manufacturing and advertising and marketing of pharmaceutical products. It focuses on production products throughout therapeutic regions of breathing, dermatology and oncology. It is involved in development of new chemical entities (NCEs) and new biological entities (NBEs). Its business segments consist of India, North America, Europe and Rest of the world. It is centered on developing and advertising branded and universal formulations. Its products consist of FabiFlu, Ryaltris and Remo (Remogliflozin etabonate). Its FabiFlu is an antiviral remedy to treat slight to moderate COVID-19. Its Ryaltris is a set-dose aggregate nasal spray of an antihistamine (olopatadine hydrochloride 665 microgram) and a steroid that treats signs and symptoms associated with seasonal, in addition to perennial allergic rhinitis. Its Remo is a sodium-glucose shipping-2 (SGLT2) inhibitor for the sort 2 diabetes.

Read More..

Glenmark Pharma Share Price

New

₹ | |

Volume
Price

Quarterly Price

Quarterly Monthly
Show Value Show %

Peer Comparison

Glenmark Pharma Quarterly Results

#(Fig in Cr.) Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025
Net Sales 3001 3036 3207 2507 3063 3244 3434 3388 3256 3264
Other Income -42 20 2 45 773 31 39 31 12 26
Total Income 2958 3056 3209 2552 3836 3276 3473 3419 3268 3291
Total Expenditure 2603 2599 2745 2715 2559 2656 2832 2787 2695 2684
Operating Profit 355 457 464 -163 1278 620 641 631 573 607
Interest 109 112 121 134 149 40 48 52 67 58
Depreciation 135 142 141 147 151 118 120 123 125 130
Exceptional Income / Expenses -800 -52 -325 -77 -447 0 0 0 -373 -323
Profit Before Tax -688 151 -124 -521 531 462 473 456 8 96
Provision for Tax -139 114 56 -72 1769 122 118 108 4 49
Profit After Tax -549 38 -180 -450 -1239 340 354 348 4 47
Adjustments 121 112 98 98 20 0 -0 -0 0 -0
Profit After Adjustments -428 150 -82 -351 -1218 340 354 348 5 47
Adjusted Earnings Per Share -15.2 5.3 -2.9 -12.5 -43.2 12.1 12.6 12.3 0.2 1.7

Glenmark Pharma Profit & Loss

#(Fig in Cr.) Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 TTM
Net Sales 6681 7562 9079 9074 9865 10641 10944 12305 11583 11813 13322 13342
Other Income 7 20 37 91 208 160 50 167 289 840 114 108
Total Income 6688 7582 9117 9166 10074 10801 10994 12472 11872 12653 13435 13451
Total Expenditure 5467 6125 7043 7459 8280 8943 8860 9985 9948 10618 10970 10998
Operating Profit 1221 1457 2074 1707 1794 1858 2135 2487 1924 2035 2465 2452
Interest 190 179 237 286 335 377 353 298 349 516 207 225
Depreciation 300 234 264 302 326 417 444 487 569 582 486 498
Exceptional Income / Expenses -187 0 -81 0 167 33 45 -261 -766 -901 -373 -696
Profit Before Tax 544 1044 1491 1119 1301 1096 1382 1441 240 36 1399 1033
Provision for Tax 334 301 383 315 376 320 412 448 329 1867 352 279
Profit After Tax 209 743 1109 804 925 776 970 994 -90 -1831 1047 753
Adjustments 0 0 0 -0 -0 -0 -0 -52 387 329 -0 0
Profit After Adjustments 210 743 1109 804 925 776 970 942 297 -1502 1047 754
Adjusted Earnings Per Share 7.7 26.3 39.3 28.5 32.8 27.5 34.4 33.4 10.5 -53.2 37.1 26.8

Growth Rates

# 1 Year 3 Year 5 Year 10 Year
Sales CAGR 13% 3% 5% 7%
Operating Profit CAGR 21% -0% 6% 7%
PAT CAGR 0% 2% 6% 17%
# 1 Year 3 Year 5 Year 10 Year
Share Price CAGR 8% 67% 31% 6%
ROE Average 13% -3% 4% 12%
ROCE Average 16% 8% 11% 14%

Glenmark Pharma Balance Sheet

#(Fig in Cr.) Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Shareholder's Funds 1783 3630 4493 5163 5605 6071 7065 9087 9474 7848 8849
Minority's Interest -0 -0 -0 -0 -0 -0 -0 351 365 -0 -0
Borrowings 2574 2487 4536 4142 3574 4043 3889 2572 3852 0 513
Other Non-Current Liabilities 175 -988 -1279 -1318 -1294 -1010 -1085 -1302 -1231 -357 -403
Total Current Liabilities 3777 3999 2703 3288 4021 4126 4201 4689 4546 5819 5967
Total Liabilities 8309 9128 10453 11275 11906 13229 14069 15397 17566 13309 14925
Fixed Assets 2015 2594 2755 3030 3670 5029 5129 5887 5422 4210 4487
Other Non-Current Assets 963 630 823 1257 1539 1397 1580 1228 1418 1671 1143
Total Current Assets 5331 5904 6875 6989 6697 6804 7360 8282 8424 7428 9295
Total Assets 8309 9128 10453 11275 11906 13229 14069 15397 17566 13309 14925

Glenmark Pharma Cash Flow

#(Fig in Cr.) Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Opening Cash & Cash Equivalents 795 764 857 1056 1233 936 1110 1138 1411 1443 1658
Cash Flow from Operating Activities 482 345 657 1648 1324 1392 1131 1109 625 -265 -828
Cash Flow from Investing Activities -540 -880 -712 -1013 -699 -784 -675 -333 -528 4561 2
Cash Flow from Financing Activities 199 699 543 -468 -739 -445 -442 -520 -77 -3906 787
Net Cash Inflow / Outflow 141 163 488 166 -114 164 14 255 19 389 -38
Closing Cash & Cash Equivalent 764 857 1056 1233 936 1110 1138 1411 1443 1658 1676

Glenmark Pharma Ratios

# Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Earnings Per Share (Rs) 7.72 26.34 39.3 28.49 32.78 27.5 34.38 33.37 10.53 -53.21 37.11
CEPS(Rs) 18.79 34.64 48.66 39.19 44.33 42.28 50.1 52.46 17 -44.26 54.33
DPS(Rs) 2 2 2 2 2 2.5 2.5 2.5 2.5 2.5 2.5
Book NAV/Share(Rs) 65.74 128.59 159.16 182.62 198.27 214.65 249.6 321.45 335.13 277.46 313.28
Core EBITDA Margin(%) 17.96 18.79 22.17 17.75 16.07 15.96 8.26 8.35 5.79 4.31 8.01
EBIT Margin(%) 10.85 15.99 18.82 15.43 16.58 13.85 6.88 6.26 2.09 1.99 5.47
Pre Tax Margin(%) 8.04 13.65 16.24 12.3 13.18 10.3 5.48 5.18 0.85 0.13 4.77
PAT Margin (%) 3.1 9.71 12.07 8.83 9.38 7.29 3.84 3.57 -0.32 -6.61 3.57
Cash Profit Margin (%) 7.54 12.78 14.95 12.15 12.68 11.21 5.6 5.32 1.7 -4.51 5.22
ROA(%) 2.58 8.52 11.33 7.4 7.98 6.17 7.11 6.74 -0.54 -11.86 7.42
ROE(%) 8.79 27.46 27.31 16.67 17.21 13.32 14.81 12.33 -0.97 -21.18 12.56
ROCE(%) 12.4 18.53 20.54 14.77 16.47 14.04 15.3 14.19 4.43 4.88 16.16
Receivable days 125.97 119.39 97.29 94.95 83.73 78.95 36.01 37.24 43.76 36.38 32.34
Inventory Days 59.42 67.68 73.65 83.59 79.22 75.25 31.9 31.35 31.52 32.19 34.46
Payable days 353.59 310.27 263.45 221.98 226.86 218.9 219.98 191.57 186.18 190.23 217.75
PER(x) 101.76 30.15 21.83 18.51 19.69 7.49 13.51 13.25 44.14 0 41.5
Price/Book(x) 11.96 6.18 5.39 2.89 3.26 0.96 1.86 1.38 1.39 3.45 4.92
Dividend Yield(%) 0.25 0.25 0.23 0.38 0.31 1.21 0.54 0.57 0.54 0.26 0.16
EV/Net Sales(x) 3.64 3.38 3.07 2.01 2.2 0.9 1.52 1.2 1.41 2.23 3.3
EV/Core EBITDA(x) 19.94 17.53 13.44 10.71 12.11 5.15 7.8 5.93 8.48 12.95 17.83
Net Sales Growth(%) 12.38 13.18 20.07 -0.06 8.72 7.86 2.85 12.44 -5.86 1.98 12.77
EBIT Growth(%) -17.14 66.67 41.37 -18.73 16.39 -9.9 17.8 0.22 -66.14 -6.18 190.75
PAT Growth(%) -61.61 254.72 49.22 -27.5 15.07 -16.11 25.02 2.43 -109.01 -1944.25 157.19
EPS Growth(%) -61.37 241.03 49.18 -27.51 15.08 -16.11 25.01 -2.92 -68.44 -605.16 169.73
Debt/Equity(x) 2.13 1.1 1.05 0.9 0.8 0.8 0.67 0.4 0.46 0.13 0.25
Current Ratio(x) 1.41 1.48 2.54 2.13 1.67 1.65 1.75 1.77 1.85 1.28 1.56
Quick Ratio(x) 1.08 1.08 1.75 1.51 1.11 1.13 1.21 1.23 1.33 0.84 1.05
Interest Cover(x) 3.86 6.84 7.28 4.92 4.89 3.9 4.92 5.83 1.69 1.07 7.76
Total Debt/Mcap(x) 0.18 0.18 0.2 0.31 0.24 0.84 0.36 0.29 0.33 0.04 0.05

Glenmark Pharma Shareholding Pattern

# Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025
Promoter 46.65 46.65 46.65 46.64 46.65 46.65 46.65 46.65 46.65 46.65
FII 25.52 24.8 23.71 21.38 20.98 23.05 23.51 23.16 20.62 20.73
DII 9.15 10.35 10.95 13.4 13.96 13.25 13.89 14.64 17.67 18.65
Public 18.69 18.21 18.69 18.58 18.41 17.06 15.96 15.56 15.06 13.97
Others 0 0 0 0 0 0 0 0 0 0
Total 100 100 100 100 100 100 100 100 100 100

Pros

  • Company is almost debt free.

Cons

  • Promoter holding is low: 46.65%.
  • Company has a low return on equity of -3% over the last 3 years.
  • Debtor days have increased from 190.23 to 217.75days.
  • Stock is trading at 5.9 times its book value.
  • The company has delivered a poor profit growth of 6% over past five years.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Glenmark Pharma News

IPO

Companies Open Date Close Date Issue Price Cost of 1 Lot Listing Price Listing Gain(%) Current Price Return (%) Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot Listing Price Listing Gain(%) Current Price Return (%) Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot Listing Price Listing Gain(%) Current Price Return (%) Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot Listing Price Listing Gain(%) Current Price Return (%) Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot Listing Price Listing Gain(%) Current Price Return (%) Type Exchange

View more.....

You May Also Know About

Unlisted Shares Pre-IPO Shares ESOP Shares Delisted Shares

Please Login!

Click to Login
OR
Get free Account

Error!